-
公开(公告)号：US10781456B2
公开(公告)日：2020-09-22
申请号：US15737558
申请日：2016-06-22
Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. , Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science
Inventor： Arren Bar-Even , Tobias Erb , Steffen Lindner , Philippe Marliere , Dan S. Tawfik
IPC: C12N15/82
Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate,) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2. The present invention further relates to the use of an organism, tissue, cell or organelle of the invention for enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.
-
2.发明申请公开(公告)号：US20180223302A1
公开(公告)日：2018-08-09
申请号：US15737558
申请日：2016-06-22
Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. , Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science
Inventor： Arren BAR-EVEN , Tobias ERB , Steffen LINDNER , Philippe MARLIERE , Dan S. TAWFIK
IPC: C12N15/82
CPC classification number: C12N15/8269 , C12N15/8261 , Y02A40/146
Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2. The present invention further relates to the use of an organism, tissue, cell or organelle of the invention for enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.
-
公开(公告)号：US20170020998A1
公开(公告)日：2017-01-26
申请号：US15286327
申请日：2016-10-05
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE , UNIVERSITAET DUISBURG-ESSEN
Inventor： Edward H. Schuchman , Erich Gulbins , Anthony Futerman , Yael Pewzner-Jung
CPC classification number: A61K38/50 , A61K9/0014 , A61K9/0019 , A61K9/0073 , A61K9/12 , A61K45/06 , C12Y305/01023
Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
Abstract translation: 本发明涉及用于治疗或预防患有囊性纤维化，COPD和/或开放性伤口的受试者的病原体感染的方法。 该方法包括选择具有囊性纤维化，COPD和/或开放性伤口的受试者，并在有效减少神经酰胺的病症和治疗或预防病原体感染的条件下向所选受试者施用神经酰胺酶。 该方法还涉及使用神经酰胺酶与其他药物组合以减少感染，减少神经酰胺，或改善囊性纤维化，COPD和/或开放性伤口患者的肺功能。
-
公开(公告)号：US20220202919A1
公开(公告)日：2022-06-30
申请号：US17397298
申请日：2021-08-09
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE
Inventor： Edward H. Schuchman , Erich Gulbins , Anthony Futerman , Yael Pewzner-Jung
Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
-
公开(公告)号：US10933134B2
公开(公告)日：2021-03-02
申请号：US15924039
申请日：2018-03-16
Applicant: Memorial Sloan Kettering Cancer Center , Yeda Research and Development Co. Ltd., at the Weizmann Institute of Science
Inventor： Jonathan Coleman , Philip A. Watson , Kwanghee Kim , Avigdor Scherz
Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).
-
Patent Agency Ranking
6.发明申请INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE DISORDERS, CNS INJURY AND AGE-RELATED DEMENTIA 审中-公开中和神经损伤和年龄相关疾病的个体化免疫调节治疗公开(公告)号：US20150238582A1
公开(公告)日：2015-08-27
申请号：US14427089
申请日：2013-09-10
Inventor： Michal Eisenbach-Schwartz , Nir Friedman , Kuti Baruch , Gilad Kunis , Liora Cahalon , Neta Rosenzweig , Aleksandra Deczkowska
IPC: A61K39/00
CPC classification number: A61K39/0007 , A61K35/17 , A61K38/217 , A61K45/06 , A61K2039/55544 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , A61P25/28 , C07K16/2878 , C07K2317/76 , C12N5/0636 , C12N15/117 , C12N2310/17 , C12N2320/30 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2317 , C12N2501/24 , C12N2501/25 , A61K2300/00
Abstract: A method for treating a disease, disorder, condition or injury of the Central Nervous System (CNS) in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an active ingredient, such as a non-encephalitogenic or weakly encephalitogenic combination of a Th1 adjuvant and a CNS-specific antigen, causing activation of the choroid plexus of said subject and maintaining said activation by reducing immunosuppression and establishing Th1-type immune response at the choroid plexus thus allowing either anti-inflammatory immune cells or immune cells which acquire a healing phenotype at the cerebrospinal fluid to pass through the choroid plexus, and accumulate at a site of damage in the CNS caused by said disease, disorder, condition or injury is provided.
Abstract translation: 一种在有需要的受试者中治疗中枢神经系统（CNS）的疾病，病症，病症或损伤的方法，包括向所述受试者施用治疗有效量的活性成分，例如非脑炎性或弱致脑炎 Th1佐剂和CNS特异性抗原的组合，引起所述受试者的脉络丛的激活，并通过降低免疫抑制并在脉络丛上建立Th1型免疫应答来维持所述活化，从而允许抗炎免疫细胞或免疫细胞 其在脑脊液中获得愈合表型以通过脉络丛，并且在由所述疾病，病症，病状或损伤引起的CNS的损伤部位积聚。
-
公开(公告)号：US20030152564A1
公开(公告)日：2003-08-14
申请号：US10373794
申请日：2003-02-27
Inventor： Matityahu Fridkin , Eran Yavin
IPC: A61K038/55
CPC classification number: C07K14/4737 , A61K38/00
Abstract: A peptide corresponding to positions 62-71 of the sequence of human C-reactive protein (CRP) of the formula: Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71 and modifications thereof obtained by substitution, deletion, or addition of amino acids, amidation of the C-terminal or acylation of the N-terminal, are capable of inhibiting in vitro the enzymatic activity of human Leukocyte Elastase (hLE) and/or of human Cathepsin G (hCG) and can be used for the treatment of chronic inflammation conditions such as rheumatoid arthritis, pulmonary emphysema, cystic fibrosis, bronchitis, asthma and some acute respiratory distress syndrome.
Abstract translation: 对应于下式的人C-反应蛋白（CRP）序列62-71的肽：Glu62-Ile-Leu-Ile-Phe-Trp-Ser-Lys-Asp-Ile71及其通过取代获得的修饰， 氨基酸的缺失或添加，C-末端的酰胺化或N末端的酰化，能够在体外抑制人白细胞弹性蛋白酶（hLE）和/或人组织蛋白酶G（hCG）的酶活性，并且可以 用于治疗慢性炎症病症如类风湿性关节炎，肺气肿，囊性纤维化，支气管炎，哮喘和一些急性呼吸窘迫综合征。
-
公开(公告)号：US20240069042A1
公开(公告)日：2024-02-29
申请号：US18387593
申请日：2023-11-07
Applicant: NeuroQuest Ltd. , Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
Inventor： Xin Huang , Yihan Li , James Doecke , Michal Eisenbach-Schwartz , Baijun Gu
CPC classification number: G01N33/6896 , G01N33/582 , G01N2800/2821
Abstract: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD11c, CD59, CD91, and CD163 and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.
-
公开(公告)号：US20220031776A1
公开(公告)日：2022-02-03
申请号：US16644641
申请日：2018-09-07
Applicant: Keio University , BiomX Ltd. , Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science
Inventor： Kenya Honda , Koji Atarashi , Seiko Narushima , Eran Elinav , Rotem Sorek , Efrat Khabra , Hava Ben David , Eyal Weinstock , Sarah Pollock , Yulia Matiuhin , Naomi Zak
Abstract: Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.
-
公开(公告)号：US10159724B2
公开(公告)日：2018-12-25
申请号：US15286327
申请日：2016-10-05
Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE , UNIVERSITAET DUISBURG-ESSEN
Inventor： Edward H. Schuchman , Erich Gulbins , Anthony Futerman , Yael Pewzner-Jung
Abstract: The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.024 seconds)
